HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.
about
T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.Characteristics of inhibitors in mild/moderate haemophilia A.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceA close insight to factor VIII inhibitor in the congenital hemophilia A.Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.Computational modelling and inhibitor risk: predicting the future?Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional
P2860
Q30620098-B7B30E36-0B7B-46D2-A7AA-A9A199911C68Q33910694-A5DEEE33-CD0D-4CAA-BDE8-9B748EC6EAB8Q36661826-F86B0F74-64EA-446B-8B4D-EE02852EA304Q36707550-FF7A56E5-59CF-4E57-BD79-53EEE5F27AEDQ37176534-92AE8F98-7146-4BAF-BE08-F32E74D4387FQ37244126-9B266A6C-FA38-4758-A1AA-963C22A5948AQ37702836-8CD97216-8740-4AA9-9F3F-14DA151ED9D3Q38101041-3FE76DE1-2F86-4585-AE6B-23A91AF78123Q38883211-28638FB0-3177-45C6-BEE3-01DA02BB41A5Q42544183-101598D7-05EB-4D3E-849E-6B30D1CAD553Q45857166-E22D6A21-AF3A-4E92-A3C1-D513270C24E1Q45861335-DEC55F8A-BA13-4F7E-9939-D16C32D10A1FQ45878830-5A90859C-1FC2-44F6-A6AB-D3ED9E5DB986Q45884378-1E7E0668-8496-47C6-94CD-B4A27559347C
P2860
HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@en
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@nl
type
label
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@en
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@nl
prefLabel
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@en
HLA class II genotype and fact ...... ith an Arg593 to Cys mutation.
@nl
P2093
P2860
P921
P1433
P1476
HLA class II genotype and fact ...... with an Arg593 to Cys mutation
@en
P2093
Fijnvandraat K
MacLean PE
van den Brink EN
P2860
P304
P356
10.1111/J.1365-2516.2004.01011.X
P50
P577
2004-09-01T00:00:00Z